Leap Therapeutics (LPTX)
(Delayed Data from NSDQ)
$2.20 USD
+0.03 (1.38%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.19 -0.01 (-0.45%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LPTX 2.20 +0.03(1.38%)
Will LPTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LPTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LPTX
Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks
Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal
LPTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome
Perrigo (PRGO) Unit Files for OTC Birth Control Pill With FDA
Novo Nordisk's (NVO) Haemophilia A Study Meets Safety Endpoint
Other News for LPTX
Leap Therapeutics initiated with bullish view at Rodman & Renshaw
Buy Rating Affirmed for Leap Therapeutics on Strong Trial Prospects and Solid Financials
Buy Rating Affirmed for Leap Therapeutics Amid Promising Clinical Trials and Strategic Expansion
Leap Therapeutics price target lowered by $1.50 at H.C. Wainwright, here's why
LPTX Stock Earnings: Leap Therapeutics Beats EPS for Q1 2024